Results 61 to 70 of about 139,370 (300)
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation. [PDF]
Bleeding is a frequent complication in patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO). An indication for dual antiplatelet therapy due to coronary stent implantation is present in a considerable number of these patients.
Dawid L Staudacher +5 more
doaj +1 more source
Background Although current guidelines recommend dual antiplatelet therapy (DAPT) for 3 to 6 months following transcatheter aortic valve replacement (TAVR), there are no studies directly comparing outcomes of different durations of DAPT following TAVR ...
Toshiki Kuno +7 more
doaj +1 more source
Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis [PDF]
Background Both pharmaceutical costs and quality-indicator performance vary substantially between general practices, but little is known about the relationship between prescribing costs and quality Aim To measure the association between prescribing ...
Allsup +8 more
core +1 more source
HSP90α is significantly upregulated in platelets from sepsis patients, with its origin from megakaryocyte‐derived trafficking. Furthermore, activated platelets secrete HSP90α into the extracellular space in both free and exosome‐associated forms. Finally, extracellular HSP90α directly engages TLR4 on neutrophils to induce autophagy, leading to NET ...
Chengbo Wang +17 more
wiley +1 more source
Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez +41 more
core +2 more sources
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
Objective Elevated cerebrospinal fluid red blood cell counts in patients on antiplatelet therapy during lumbar puncture raise concerns about increased bleeding risk.
Qiwei Ran +3 more
doaj +1 more source
Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients. [PDF]
BACKGROUND: Until now there has been scarce evidence regarding an optimal antiplatelet strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST).
Ya-Ling Han +12 more
doaj +1 more source
Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]
Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui +4 more
core +1 more source

